| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| J Birks, V Iakovidou, M Tsolak. Rivastigmine for Alzheimer's disease. The Cochrane database of systematic reviews. issue 2. 2000-07-06. PMID:10796621. |
one of the most successful therapeutic strategies for alzheimer's disease has been the use of acetylcholinesterase inhibitors to enhance surviving cholinergic neurotransmission by inhibiting breakdown of released acetylcholine. |
2000-07-06 |
2023-08-12 |
Not clear |
| M Recanatini, A Cavalli, F Belluti, L Piazzi, A Rampa, A Bisi, S Gobbi, P Valenti, V Andrisano, M Bartolini, V Cavrin. SAR of 9-amino-1,2,3,4-tetrahydroacridine-based acetylcholinesterase inhibitors: synthesis, enzyme inhibitory activity, QSAR, and structure-based CoMFA of tacrine analogues. Journal of medicinal chemistry. vol 43. issue 10. 2000-06-29. PMID:10821713. |
in this study, we attempted to derive a comprehensive sar picture for the class of acetylcholinesterase (ache) inhibitors related to tacrine, a drug currently in use for the treatment of the alzheimer's disease. |
2000-06-29 |
2023-08-12 |
Not clear |
| L Traykov, B Tavitian, A Jobert, F Boller, F Forette, C Crouzel, L Di Giamberardino, S Pappat. In vivo PET study of cerebral [11C] methyl- tetrahydroaminoacridine distribution and kinetics in healthy human subjects. European journal of neurology. vol 6. issue 3. 2000-06-26. PMID:10210906. |
it is unclear whether the palliative effects of tetrahydroaminoacridine (tha) (tacrine, cognex) on the clinical symptoms of patients affected by alzheimer's disease (ad) are the result of its inhibitory activity on acetylcholinesterase or on other complex sites of action. |
2000-06-26 |
2023-08-12 |
human |
| L Unni, S Vicari, P Moriearty, F Schaefer, R Becke. The recovery of cerebrospinal fluid acetylcholinesterase activity in Alzheimer's disease patients after treatment with metrifonate. Methods and findings in experimental and clinical pharmacology. vol 22. issue 1. 2000-06-20. PMID:10791297. |
the recovery of cerebrospinal fluid acetylcholinesterase activity in alzheimer's disease patients after treatment with metrifonate. |
2000-06-20 |
2023-08-12 |
Not clear |
| A Golbraikh, P Bernard, J R Chrétie. Validation of protein-based alignment in 3D quantitative structure-activity relationships with CoMFA models. European journal of medicinal chemistry. vol 35. issue 1. 2000-06-19. PMID:10733609. |
3d quantitative structure-activity relationship (3d qsar) models have been derived for a series of n-benzylpiperidine derivatives which are potent acetylcholinesterase (ache) inhibitors interesting for alzheimer's disease. |
2000-06-19 |
2023-08-12 |
Not clear |
| A Rampa, A Bisi, F Belluti, S Gobbi, P Valenti, V Andrisano, V Cavrini, A Cavalli, M Recanatin. Acetylcholinesterase inhibitors for potential use in Alzheimer's disease: molecular modeling, synthesis and kinetic evaluation of 11H-indeno-[1,2-b]-quinolin-10-ylamine derivatives. Bioorganic & medicinal chemistry. vol 8. issue 3. 2000-06-01. PMID:10732965. |
acetylcholinesterase inhibitors for potential use in alzheimer's disease: molecular modeling, synthesis and kinetic evaluation of 11h-indeno-[1,2-b]-quinolin-10-ylamine derivatives. |
2000-06-01 |
2023-08-12 |
Not clear |
| K Alagiakrishnan, W Wong, P L Blanchett. Use of donepezil in elderly patients with Alzheimer's disease--a Hawaii based study. Hawaii medical journal. vol 59. issue 2. 2000-05-31. PMID:10800254. |
donepezil (aricept) is a reversible acetylcholinesterase inhibitor which is indicated for the treatment of mild to moderate dementia of the alzheimer's type. |
2000-05-31 |
2023-08-12 |
human |
| I Gélinas, S Gauthier, P A Cyru. Metrifonate enhances the ability of Alzheimer's disease patients to initiate, organize, and execute instrumental and basic activities of daily living. Journal of geriatric psychiatry and neurology. vol 13. issue 1. 2000-05-18. PMID:10753002. |
the objective of this analysis was to evaluate comprehensively the efficacy of metrifonate, a long-acting acetylcholinesterase inhibitor, in improving the ability of mild-to-moderate alzheimer's disease (ad) patients to perform activities of daily living (adls). |
2000-05-18 |
2023-08-12 |
Not clear |
| T M Sobów, I Kłoszewsk. [The costs of Alzheimer's disease treatment: the rationale of acetylcholinesterase inhibitors use?]. Psychiatria polska. vol 33. issue 5. 2000-05-17. PMID:10761441. |
[the costs of alzheimer's disease treatment: the rationale of acetylcholinesterase inhibitors use?]. |
2000-05-17 |
2023-08-12 |
Not clear |
| T M Sobów, I Kłoszewsk. [The costs of Alzheimer's disease treatment: the rationale of acetylcholinesterase inhibitors use?]. Psychiatria polska. vol 33. issue 5. 2000-05-17. PMID:10761441. |
the costs of alzheimer's disease treatment in the era of acetylcholinesterase inhibitors use are critically discussed. |
2000-05-17 |
2023-08-12 |
Not clear |
| T Kosasa, Y Kuriya, K Matsui, Y Yamanish. Inhibitory effect of orally administered donepezil hydrochloride (E2020), a novel treatment for Alzheimer's disease, on cholinesterase activity in rats. European journal of pharmacology. vol 389. issue 2-3. 2000-04-18. PMID:10688981. |
donepezil hydrochloride ((+/-)-2-[(1-benzylpiperidin-4-yl)methyl]-5, 6-dimethoxy-indan-1-one monohydrochloride: e2020: donepezil) is a potent and selective acetylcholinesterase inhibitor developed for the treatment of alzheimer's disease. |
2000-04-18 |
2023-08-12 |
rat |
| J Kaur, M Q Zhan. Molecular modelling and QSAR of reversible acetylcholines-terase inhibitors. Current medicinal chemistry. vol 7. issue 3. 2000-03-30. PMID:10637365. |
acetylcholinesterase (ache) inhibitors are an important class of medicinal agents useful for the treatment of alzheimer s disease, glaucoma, myasthenia gravis and for the recovery of neuromuscular block in surgery. |
2000-03-30 |
2023-08-12 |
Not clear |
| H Sugimoto, Y Yamanishi, Y Iimura, Y Kawakam. Donepezil hydrochloride (E2020) and other acetylcholinesterase inhibitors. Current medicinal chemistry. vol 7. issue 3. 2000-03-30. PMID:10637367. |
a wide range of evidence shows that acetylcholinesterase (ache) inhibitors can interfere with the progression of alzheimer's disease (ad). |
2000-03-30 |
2023-08-12 |
Not clear |
| P Camps, B Cusack, W D Mallender, R E El Achab, J Morral, D Muñoz-Torrero, T L Rosenberr. Huprine X is a novel high-affinity inhibitor of acetylcholinesterase that is of interest for treatment of Alzheimer's disease. Molecular pharmacology. vol 57. issue 2. 2000-03-02. PMID:10648652. |
huprine x is a novel high-affinity inhibitor of acetylcholinesterase that is of interest for treatment of alzheimer's disease. |
2000-03-02 |
2023-08-12 |
human |
| P Camps, B Cusack, W D Mallender, R E El Achab, J Morral, D Muñoz-Torrero, T L Rosenberr. Huprine X is a novel high-affinity inhibitor of acetylcholinesterase that is of interest for treatment of Alzheimer's disease. Molecular pharmacology. vol 57. issue 2. 2000-03-02. PMID:10648652. |
inhibitors of the enzyme acetylcholinesterase (ache) slow and sometimes reverse the cognitive decline experienced by individuals with alzheimer's disease. |
2000-03-02 |
2023-08-12 |
human |
| A Si. Rivastigmine: a review. Hospital medicine (London, England : 1998). vol 60. issue 10. 2000-03-02. PMID:10656066. |
the acetylcholinesterase inhibitors are the first useful and useable drugs for palliative treatment of dementia of the alzheimer type. |
2000-03-02 |
2023-08-12 |
Not clear |
| C H van Dyck, P Newhouse, W E Falk, J A Matte. Extended-release physostigmine in Alzheimer disease: a multicenter, double-blind, 12-week study with dose enrichment. Physostigmine Study Group. Archives of general psychiatry. vol 57. issue 2. 2000-02-16. PMID:10665618. |
the efficacy of extended-release physostigmine salicylate, an acetylcholinesterase inhibitor, was evaluated in 850 subjects with mild-to-moderate alzheimer disease (ad) in a multicenter trial. |
2000-02-16 |
2023-08-12 |
human |
| T Kosasa, Y Kuriya, K Matsui, Y Yamanish. Inhibitory effects of donepezil hydrochloride (E2020) on cholinesterase activity in brain and peripheral tissues of young and aged rats. European journal of pharmacology. vol 386. issue 1. 2000-02-11. PMID:10611458. |
donepezil hydrochloride (donepezil: e2020: (+/-)-2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-indan-1-one monohydrochloride)) is a centrally acting acetylcholinesterase inhibitor developed for the treatment of alzheimer's disease. |
2000-02-11 |
2023-08-12 |
rat |
| T Kosasa, Y Kuriya, Y Yamanish. Effect of donepezil hydrochloride (E2020) on extracellular acetylcholine concentration in the cerebral cortex of rats. Japanese journal of pharmacology. vol 81. issue 2. 2000-02-03. PMID:10591480. |
donepezil hydrochloride (donepezil), a potent and selective acetylcholinesterase inhibitor, has been developed for the treatment of alzheimer's disease. |
2000-02-03 |
2023-08-12 |
rat |
| Y Li, L Liu, J Kang, J G Sheng, S W Barger, R E Mrak, W S Griffi. Neuronal-glial interactions mediated by interleukin-1 enhance neuronal acetylcholinesterase activity and mRNA expression. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 20. issue 1. 2000-01-27. PMID:10627591. |
cholinergic dysfunction in alzheimer's disease has been attributed to stress-induced increases in acetylcholinesterase (ache) activity. |
2000-01-27 |
2023-08-12 |
rat |